Pharvaris (NASDAQ:PHVS) Given “Buy” Rating at HC Wainwright

Pharvaris (NASDAQ:PHVS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $60.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 112.86% from the stock’s previous close.

A number of other analysts have also recently issued reports on the company. Morgan Stanley boosted their price objective on Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Bank of America raised shares of Pharvaris from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $16.00 to $27.00 in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Wedbush upped their price objective on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.57.

Pharvaris Trading Up 16.9%

PHVS traded up $4.07 during trading on Wednesday, hitting $28.19. The stock had a trading volume of 2,798,852 shares, compared to its average volume of 141,256. The firm has a market cap of $1.47 billion, a PE ratio of -8.77 and a beta of -2.80. Pharvaris has a 12 month low of $11.51 and a 12 month high of $28.82. The company has a 50 day simple moving average of $23.60 and a 200-day simple moving average of $21.42.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.08. As a group, sell-side analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

Hedge funds have recently modified their holdings of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris in the second quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris during the 3rd quarter worth $75,000. Public Employees Retirement System of Ohio lifted its holdings in Pharvaris by 39.3% during the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after acquiring an additional 1,769 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after acquiring an additional 1,695 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.